Immunic, Inc. · NASDAQ:IMUX
Immunic — 3rd B & T Cell-Mediated Autoimmune Disease Drug Development Summit (July 2022)
29 slides from Immunic's conference presentation, Jul 28, 2022
Slide 1: IMU-935, a Potent RORgt Inverse Agonist, Inhibits T Helper 17 Cells but Maintains Normal Thymocyte Development
IMU-935, a Potent RORgt Inverse Agonist, Effectively Inhibits T Helper 17 Cells but Maintains Normal Thymocyte Development Evelyn Peelen, Ph.D. | Immunic Therapeutics | NASDAQ: IMUX July 28, 2022 | 3rd B & T Cell-Mediated Autoimmune Disease Drug Development Summit
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Slide 3: Company Introduction
1 Immunic Therapeutics Company Introduction
Slide 4: Our Mission
Our Mission We are developing a pipeline of next- generation selective oral therapies focused on offering patients with chronic inflammatory and autoimmune diseases new and clinically meaningful treatment options. 4 | © Immunic, Inc. | Jul/28/2022
Slide 5: Multiple Clinical Data Readouts Expected Throughout 2022
Multiple Clinical Data Readouts Expected Throughout 2022 Program Target Preclinical Phase 1 Phase 2 Phase 3 Key Milestones Relapsing Multiple Sclerosis (RMS) – ENSURE Trials § RMS interim analysis planned after approx. half of the events occurred Vidofludimus Calcium DHODH Progressive Multiple Scler
Slide 6: IMU-935 Overview
2 IMU-935 Overview Mode of Introduction Action – In Vitro Mode of Phase 1 Conclusions Action – In Vivo
Slide 7: The Nuclear Retinoic Acid Receptor-Related Orphan Receptor (ROR) Gamma (RORg)
The Nuclear Retinoic Acid Receptor-Related Orphan Receptor (ROR) Gamma (RORg) Ø RORg is encoded by the gene RORC and consists of two isoforms § RORg1: full length 518 aa § RORgt (RORg2): lacks the first 21 aa. It is mainly expressed by T cells, but also in some other immune cells and is involved in
Slide 8: Clear Need for Potent and Specific Inhibition of IL-17 in Multiple Autoimmune Diseases
Clear Need for Potent and Specific Inhibition of IL-17 in Multiple Autoimmune Diseases IL-17 is Significant in Many Goal: Develop a Potent, Specific, and Autoimmune Diseases Orally Available IL-17 Inhibitor § Imbalance between regulatory T cells (Tregs) and T helper 17 (TH17) cells contributes to Un
Slide 9: IMU-935 Overview
3 IMU-935 Overview Mode of Introduction Action – In Vitro Mode of Phase 1 Conclusions Action – In Vivo
Slide 10: IMU-935 Inhibits Cytokines Associated With Autoimmune Diseases With an IC50 of 3-5 nM
IMU-935 Inhibits Cytokines Associated With Autoimmune Diseases With an IC50 of 3-5 nM in Stimulated Human Lymphocytes IC50 (µM) IL-17A 0.005 IL-17F 0.004 IFNγ 0.003 IL-1a and b no inhibition IL-4,5,6,8 no inhibition RORγ (MST) 0.024 RORγ (cellular, reporter assay) 0.020 Th17 differentiation (murine)
Slide 11: IMU-935 Potently Inhibits Human and Murine IL-17 and TH17 Cells
IMU-935 Potently Inhibits Human and Murine IL-17 and TH17 Cells Ø Strong inhibition of human IL-17A (EC50: 5 nM) and IL-17F (EC50: 4 nM) secretion and murine TH17 cell differentiation (EC50: 135 nM) IL-17F Secretion Intracellular IL-17A and IL-17F Human Primary PBMCs in murine CD4+ T cells 40 40 **
Slide 12: Potently Inhibits TH17 Cell Differentiation but Does Not Induce Thymocyte Apoptosis
IMU-935 Potently Inhibits TH17 Cell Differentiation but Does Not Induce Thymocyte Apoptosis In contrast to IMU-935, comparator compounds have a negative impact on thymocyte viability and therefore bear the risk of lymphoma. 18 24 30 36 me (h) * *** ** U-935 RORγt-/- IMU-935 d1 140 140 140 140 140 14
Slide 13: Does Not Impair Thymocyte Maturation In Vitro
IMU-935 Does Not Impair Thymocyte Maturation In Vitro In contrast to IMU-935, comparator compounds have also a negative impact on thymocyte maturation and therefore bear the risk of lymphoma. * *** ** IMU-935 60 ** Sorted Thy1.2+CD4- Compared to the reference compounds, CD4+ Thymocytes (%) 40 CD8- t
Slide 14: IMU-935 Attenuates RORγt Genome-Wide DNA-Binding in TH17 Cells
IMU-935 Attenuates RORγt Genome-Wide DNA-Binding in TH17 Cells ⎼ No DNA binding in RORgt-/- or RORgt+/+ with IMU-935 RORγt-/- (EV) RORγt+/+ RORγt+/+ + IMU-935 RORγt-/- RORγt+/+ RORγt+/+ +IMU-935 TSS plot: a common visualization method to obtain a global evaluation of enrichment around the transcript
Slide 15: IMU-935 Does Not Affect RORgt Target Genes Critical for Thymocyte Function
IMU-935 Does Not Affect RORgt Target Genes Critical for Thymocyte Function ⎼ DNA Binding in WT with and without IMU-935 RORγt-/- WT WT + IMU-935 § RORγt protein binds to many gene loci in murine thymocytes § RORγt protein binds to a similar number and to a similar extent to DNA loci in murine thymoc
Slide 16: Blocks Th17 Differentiation But Allows Normal Thymocyte Maturation: Gene Expression Profiles
IMU-935 Blocks Th17 Differentiation But Allows Normal Thymocyte Maturation: Gene Expression Profiles Thymocytes Th17 cell WT + RORγt-/- WT IMU-935 RORγt+/+- RORγt-/- RORγt+/+ IMU-935 IMU-935 Apoptosis Th17 signature genes Anti-apoptosis/ survival Similar gene expression pattern for Th17 signature Di
Slide 17: IMU-935 Potently Inhibited Cytokine Release in Ex Vivo Stimulated Human Skin Punches
IMU-935 Potently Inhibited Cytokine Release in Ex Vivo Stimulated Human Skin Punches Cytokine Inhibition in Inflamed Human Skin Model IMU-935 is active with < 100 nM on GM-CSF IL-17A IL-17F Method: Result: Skin punches from a human healthy volunteer were ex vivo IMU-935 demonstrated a strong inhibit
Slide 18: IMU-935 Overview
4 IMU-935 Overview Mode of Introduction Action – In Vitro Mode of Phase 1 Conclusions Action – In Vivo
Slide 19: IMU-935 Showed Histological Improvement and Reduction in IL-17F Expression in Imiquimod Mouse Model
IMU-935 Showed Histological Improvement and Reduction in IL- 17F Expression in Skin an Imiquimod Induced Mouse Model Male 30/60 mg/kg qd 62.5 mg 5% IMQ Reduction of histological score on ear and skin C57BL6 Systemic exposure leads to dose dependent inhibition of IL-17F mRNA expression in vivo in the
Slide 20: IMU-935 Demonstrated Activity in an Imiquimod Induced Psoriasis Model
IMU-935 Demonstrated Activity in an Imiquimod Induced Psoriasis Model 5 mg/kg 5 mg/kg 5 mg/kg 5 mg/kg Female 10/100 mg/kg § IMU-935 benchmarked with an IL-17A antibody (InVivoMab, Clone: 17F3), 50 mg 5% IMQ demonstrating superiority of IMU-935 on skin thickness at day 8 BALB/cJ § Interestingly, the
Slide 21: IMU-935 Allows Normal Thymocyte Maturation In Vivo
IMU-935 Allows Normal Thymocyte Maturation In Vivo § Acute model: Treatment with IMU-935 (100 mg/kg), MRL-871 (100 mg/kg), or Cintirorgon (30 mg/kg) for 3 days (BID) 15 Thymic cellularity (x107) 12 9 In contrast to 6 ** MRL-871 and Cpd1, IMU-935 does not impact 3 0 thymus size, thymocyte cell Vehicl
Slide 22: IMU-935 Overview
5 IMU-935 Overview Mode of Introduction Action – In Vitro Mode of Phase 1 Conclusions Action – In Vivo
Slide 23: Phase 1 Clinical Trial: Trial Design and Current Status
Phase 1 Clinical Trial: Trial Design and Current Status PART A PART B PART C Evaluation of Evaluation of Evaluation of single ascending doses (SAD) multiple ascending doses (MAD) moderate-to-severe psoriasis patients receiving 28-day Healthy human subjects Healthy human subjects treatment of randomi
Slide 24: Phase 1 Clinical Trial: Pharmacokinetic Results
Phase 1 Clinical Trial: Pharmacokinetic Results Part B: Summary of QD and BID Dosing Regimen for IMU-935 IMU-935 concentration time profiles (log-linear scale) Favorable PK Properties for IMU-935 at Time [days] Steady-State Observed 0 7 14 Pharmacokinetic parameters 150 mg QD 150 mg BID Mean plasma
Slide 25: Phase 1 Clinical Trial: Summary of Safety and Tolerability Findings
Phase 1 Clinical Trial: Summary of Safety and Tolerability Findings Part B Daily Dosing of IMU-935 in Healthy Human Subjects Over 14 Days Was Found to Have a Favorable Safety and Tolerability Profile No serious adverse events No dose-dependency in adverse events No maximum tolerated dose reached No
Slide 26: Phase 1 Clinical Trial: Part C in Moderate-to-Severe Psoriasis Patients
IMU-935 Phase 1 Clinical Trial Part C in Moderate-to-Severe Psoriasis Patients Detecting Therapeutic Activity of IMU-935 in Moderate-to-Severe Psoriasis Patients § Double-blind, placebo-controlled dose escalation study to evaluate safety, tolerability, pharmacodynamics and exploratory efficacy of IM
Slide 27: IMU-935 Overview
6 IMU-935 Overview Mode of Introduction Action – In Vitro Mode of Phase 1 Conclusions Action – In Vivo
Slide 28: IMU-935 Selectively Inhibits TH17 Differentiation and IL-17 Secretion
IMU-935 Selectively Inhibits TH17 Differentiation and IL-17 Secretion IMU - Bloc 935 ks TH Differentiation TH17 The differentiation towards TH17 cells is inhibited by IMU-935 IMU - Bloc 935 ks TH Cytokine TH17 IL-17A The production of IL-17A and IL-17F Production IFN-g IL-17F is inhibited by IMU-935
Slide 29: Thank You!
Thank You! Immunic, Inc. 1200 Avenue of the Americas Immunic AG New York City, NY 10036 Gräfelfing (Munich) USA Germany Immunic Research GmbH Weinberg Campus Evelyn Peelen, Ph.D. Halle (Saale) Germany Senior Manager Translational Collaborators Pharmacology at City of Hope Phone: +49 89 2080 477 27 P
Immunic — 3rd B & T Cell-Mediated Autoimmune Disease Drug Development Summit (July 2022) on 6ix